Generic Version of Perforomist Now Available
The first authorized generic version of Perforomist® (formoterol fumarate inhalation solution; Mylan Specialty L.P.) 20mcg/2mL has been made available by Teva Pharmaceuticals.
Chronic Obstructive Pulmonary Disease
Asthma, COPD Do Not Increase Mortality Risk in Patients With COVID-19
Asthma and chronic obstructive pulmonary disease (COPD) do not appear to increase the risk of mortality in patients with COVID-19.
Single-Inhaler Triple Therapy Reduces Composite AE Risk vs Dual Therapy in COPD
Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations.
Effect of Blood Eosinophil Counts on COPD Clinical Outcomes
Patients with COPD who exhibit low blood eosinophil counts had no change in exacerbations or survival compared with patients with typical counts.
Worse Pulmonary Function Associated With Lower Survival Rates in Lung Cancer
Patients with lung cancer and poor pulmonary function at diagnosis have worse rates of overall survival.
Dual Bronchodilation vs Triple Therapy Evaluated for Mortality Rates in COPD
Both dual bronchodilation and triple therapy demonstrated similar rates of mortality in patients with moderate to severe COPD at low risk for exacerbations.
COPD Case-Finding Tool Validated, Ready for Use in Primary Care
Use of the COPD case-finding tool, CAPTURE, in US primary care practice demonstrated ability to provide critical in-study information to help guide protocol adjustment based on unforeseen events and to clearly outline COPD diagnostic processes.
Asthma, COPD Disease Severity May Increase Risk of Developing Severe COVID-19
Disease severity of both chronic obstructive pulmonary disease (COPD) and asthma may increase the risk of the development of severe coronavirus disease 2019 (COVID-19).
New Drug Product: Breztri Aerosphere
This slideshow shows drug information for Breztri Aerosphere. Click here for the complete Breztri Aerosphere monograph.
Pulmonary Hypertension May Increase In-Hospital Mortality in Acute COPD Exacerbations
Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.
